Vaccinations in the newborn

Tejasvi Chaudhari*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    9 Citations (Scopus)

    Abstract

    Neonatal immunisation includes vaccination in the first 4 weeks of life (Neonatal period) as well as in high-risk preterm infants in the first few months (until 44 weeks corrected gestational age). Neonates have an immature immune system, which renders them highly susceptible to life-threatening infections. This highlights the importance of vaccination in this vulnerable population; however, at the same time also making it challenging because of their inability to generate a protective immune response. Other challenges include interference from maternal antibodies and excessive skewing towards T Helper Cell Type 2 (Th2) immunity. Despite these challenges, several vaccines have been developed and proven safe and effective at birth. Presently, there are 3 vaccines – Hepatitis B vaccine, Bacillus Calmette-Guerine (BCG) and Oral Polio vaccine (OPV) widely used in neonates, which provides evidence that certain antigen-adjuvant combinations can elicit protective neonatal responses. This review focusses on current vaccinations in neonates, including preterm infants and highlights some novel approaches to enhance neonatal vaccination.

    Original languageEnglish
    Pages (from-to)66-82
    Number of pages17
    JournalBest Practice and Research: Clinical Obstetrics and Gynaecology
    Volume76
    DOIs
    Publication statusPublished - Oct 2021

    Fingerprint

    Dive into the research topics of 'Vaccinations in the newborn'. Together they form a unique fingerprint.

    Cite this